Cargando…

Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome

AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob, Joseph, Aksman, Leon, Mogulkoc, Nesrin, Procter, Alex J, Gholipour, Bahareh, Cross, Gary, Barnett, Joseph, Brereton, Christopher J, Jones, Mark G, van Moorsel, Coline H, van Es, Wouter, van Beek, Frouke, Veltkamp, Marcel, Desai, Sujal R, Judge, Eoin, Burd, Teresa, Kokosi, Maria, Savas, Recep, Bayraktaroglu, Selen, Altmann, Andre, Wells, Athol U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402558/
https://www.ncbi.nlm.nih.gov/pubmed/32345689
http://dx.doi.org/10.1136/thoraxjnl-2019-213865
_version_ 1783566782542381056
author Jacob, Joseph
Aksman, Leon
Mogulkoc, Nesrin
Procter, Alex J
Gholipour, Bahareh
Cross, Gary
Barnett, Joseph
Brereton, Christopher J
Jones, Mark G
van Moorsel, Coline H
van Es, Wouter
van Beek, Frouke
Veltkamp, Marcel
Desai, Sujal R
Judge, Eoin
Burd, Teresa
Kokosi, Maria
Savas, Recep
Bayraktaroglu, Selen
Altmann, Andre
Wells, Athol U
author_facet Jacob, Joseph
Aksman, Leon
Mogulkoc, Nesrin
Procter, Alex J
Gholipour, Bahareh
Cross, Gary
Barnett, Joseph
Brereton, Christopher J
Jones, Mark G
van Moorsel, Coline H
van Es, Wouter
van Beek, Frouke
Veltkamp, Marcel
Desai, Sujal R
Judge, Eoin
Burd, Teresa
Kokosi, Maria
Savas, Recep
Bayraktaroglu, Selen
Altmann, Andre
Wells, Athol U
author_sort Jacob, Joseph
collection PubMed
description AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise. METHODS: In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines. RESULTS: On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent. CONCLUSIONS: Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines.
format Online
Article
Text
id pubmed-7402558
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74025582020-08-17 Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome Jacob, Joseph Aksman, Leon Mogulkoc, Nesrin Procter, Alex J Gholipour, Bahareh Cross, Gary Barnett, Joseph Brereton, Christopher J Jones, Mark G van Moorsel, Coline H van Es, Wouter van Beek, Frouke Veltkamp, Marcel Desai, Sujal R Judge, Eoin Burd, Teresa Kokosi, Maria Savas, Recep Bayraktaroglu, Selen Altmann, Andre Wells, Athol U Thorax Interstitial Lung Disease AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise. METHODS: In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines. RESULTS: On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent. CONCLUSIONS: Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines. BMJ Publishing Group 2020-08 2020-04-28 /pmc/articles/PMC7402558/ /pubmed/32345689 http://dx.doi.org/10.1136/thoraxjnl-2019-213865 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Interstitial Lung Disease
Jacob, Joseph
Aksman, Leon
Mogulkoc, Nesrin
Procter, Alex J
Gholipour, Bahareh
Cross, Gary
Barnett, Joseph
Brereton, Christopher J
Jones, Mark G
van Moorsel, Coline H
van Es, Wouter
van Beek, Frouke
Veltkamp, Marcel
Desai, Sujal R
Judge, Eoin
Burd, Teresa
Kokosi, Maria
Savas, Recep
Bayraktaroglu, Selen
Altmann, Andre
Wells, Athol U
Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title_full Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title_fullStr Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title_full_unstemmed Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title_short Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
title_sort serial ct analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
topic Interstitial Lung Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402558/
https://www.ncbi.nlm.nih.gov/pubmed/32345689
http://dx.doi.org/10.1136/thoraxjnl-2019-213865
work_keys_str_mv AT jacobjoseph serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT aksmanleon serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT mogulkocnesrin serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT procteralexj serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT gholipourbahareh serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT crossgary serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT barnettjoseph serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT breretonchristopherj serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT jonesmarkg serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT vanmoorselcolineh serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT vaneswouter serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT vanbeekfrouke serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT veltkampmarcel serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT desaisujalr serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT judgeeoin serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT burdteresa serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT kokosimaria serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT savasrecep serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT bayraktarogluselen serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT altmannandre serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome
AT wellsatholu serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome